Article Text

Download PDFPDF

321 Maintenance olaparib for BRCA-mutated ovarian cancer (OC) patients in 1st line and platinum-sensitive relapsed (PSR) settings: maximizing treatment opportunities
  1. A Poveda1,
  2. A Sackeyfio2 and
  3. M Friedlander3
  1. 1Initia Oncology, Department of Gynecologic Oncology, Valencia, Spain
  2. 2AstraZeneca, Health Economics and Payer Analytics, Cambridge, UK
  3. 3Prince of Wales Hospital, University of New South Wales Clinical School, Randwick, Australia


Objectives In Phase III randomized trials, maintenance therapy with the PARP inhibitor olaparib demonstrated a significant benefit versus placebo in BRCA-mutated advanced OC patients who had a complete/partial response to platinum-based chemotherapy (PBC) in newly diagnosed (SOLO1; NCT01844986) and PSR (SOLO2/ENGOT-Ov21; NCT01874353) settings. We investigate missed opportunities for maintenance olaparib in relapsed settings.

Methods Published response rates to PBC in newly diagnosed BRCA-mutated advanced OC are scarce. These are estimated by applying a BRCA response rate factor determined from a population-based study (Alsop et al) to expected PBC response rates in newly diagnosed high grade serous OC (75%). For BRCA-mutated PSR OC, response to second-line PBC was 64.6% (Alsop et al). Platinum sensitivity for second-line PBC eligibility was determined from placebo patients in SOLO1 remaining progression free after 6 months (80.6%).

Results In newly diagnosed and PSR settings, predicted proportions of eligible patients for olaparib are 84% and 44%, respectively (table 1). Missed treatment opportunities in PSR settings are likely due to platinum resistance and non-response to second-line PBC. Approximately 48% of patients could miss the opportunity to benefit from PARP inhibitor maintenance if untreated in the first line.

Abstract 321 Table 1

Conclusions Earlier olaparib therapy provides the chance of long-term remission and prevents patients missing opportunities for second-line PARP inhibitor maintenance due to platinum resistance or non-response to PBC. Disease burden associated with multiple chemotherapy lines in advanced settings is also reduced or delayed.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.